awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38550459-023D9A34-1FD1-44A9-B632-90DB033BB81C
Q38550459-023D9A34-1FD1-44A9-B632-90DB033BB81C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38550459-023D9A34-1FD1-44A9-B632-90DB033BB81C
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.
P2860
Q38550459-023D9A34-1FD1-44A9-B632-90DB033BB81C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38550459-023D9A34-1FD1-44A9-B632-90DB033BB81C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
322ab9d82bcb68582a7bfacfa1238668b22b667c
P2860
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.